Biomarin Pharmaceutical Inc./ US09061G1013 /
| 2024-05-15 7:57:14 AM | Chg. -0.9600 | Volume | Bid9:59:58 PM | Ask9:59:58 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 73.6200EUR | -1.29% | - Turnover: - |
73.8600Bid Size: 160 | 73.8800Ask Size: 160 | 14.11 bill.EUR | - | - |
Fundamentals
| FY 2023 | Growth (1Y) | |
|---|---|---|
| Per Share | ||
| Earnings per Share: | 0.89 USD | 17.11% |
| EPS Diluted: | 0.87 USD | 16.00% |
| Revenues per Share: | 12.82 USD | 14.11% |
| Book Value per Share: | 26.24 USD | 6.34% |
| Cash Flow per Share: | 0.84 USD | -10.49% |
| Dividend per Share: | - USD | - |
| Total | in mill. | |
| Revenues: | 2,419.23 USD | 15.42% |
| Net Income: | 167.65 USD | 18.43% |
| Operating Cash Flow: | 159.26 USD | - |
| Cash and Cash Equivalents: | 755.13 USD | - |
Valuation Ratios
| Current | Latest FY* | |
|---|---|---|
| P/E Ratio: | 90.34 | 108.34 |
| P/S Ratio: | 6.27 | 7.52 |
| P/BV ratio: | 3.06 | 3.67 |
| P/CF Ratio: | 95.25 | 114.23 |
| PEG: | 5.28 | 6.33 |
| Earnings Yield: | 1.11% | 0.92% |
| Dividend Yield: | - | - |
| Market Capitalization | ||
| Market Capitalization: | 14.11 bill. EUR | 16.48 bill. EUR |
| Free Float Market Cap.: | - EUR | - EUR |
| Market Cap. / Employee: | - EUR | - EUR |
| Shares Outstanding: | 189.88 mill. | |
Profitability
| Gross Profit Margin: | 78.72% |
| EBIT Margin: | 6.54% |
| Net Profit Margin: | 6.93% |
| Return on Equity: | 3.39% |
| Return on Assets: | 2.45% |
Financial Strength
| Liquidity I / Cash Ratio: | 64.16% |
| Liquidity II / Quick Ratio: | 118.00% |
| Liquidity III / Current Ratio: | 251.15% |
| Debt / Equity Ratio: | 38.17% |
| Dynam. Debt / Equity Ratio: | 1,186.78% |
Efficiency
| Employees: | - |
| Personal Expenses / Employee: | - USD |
| Revenues / Employee: | - USD |
| Net Income / Employee: | - USD |
| Total Assets / Employee: | - USD |
| * Fiscal Year End: | 2023-12-31 |
| Accounting Standard: | US GAAP |
| Currency: | USD |
